Drugs / TECHNETIUM TC-99M ETHYLENE-DICYSTEINE-DEOXYGLUCOSE
TECHNETIUM TC-99M ETHYLENE-DICYSTEINE-DEOXYGLUCOSE
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01359267 | Apr 2011 → Sep 2015 | head and neck cancer | University of Chicago | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01394679 | May → Dec 2025 overdue | lung cancer | Cell>Point LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TECHNETIUM TC-99M ETHYLENE-DICYSTEINE-DEOXYGLUCOSE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594361 ↗ |
| Known as | 99m Tc-EC-DG | “99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and \< 1 mg EC-DG” NCT01394679 ↗ |
| Known as | ECDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01394679 ↗ |
| Known as | Technetium-99m Ethylenedicysteine-Deoxyglucose | “One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG” NCT01394679 ↗ |
| Modality | Diagnostic / imaging agent | “potential of 99m Tc-EC-DG SPECT imaging to distinguish cancer from non cancer.” NCT01359267 ↗ |
| Route | Intravenous | “will be administered through a vein through a catheter.” NCT01359267 ↗ |